Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Zagam

Executive Summary

Mylan "has indicated that they are presently marketing the antibiotic Zagam and it remains a part of their Bertek branded product line," the company stated Feb. 16. The generics manufacturer previously indicated that it was discontinuing Zagam (1"The Pink Sheet" Feb. 5, p. 29). Mylan said it wrote down $3.6 mil. of the Zagam (sparfloxacin) product license in its Jan. 30 third quarter report because of "supply issues," and that it "continues to work to try to resolve the issues surrounding Zagam"
Advertisement

Related Content

Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits
Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits
Advertisement
UsernamePublicRestriction

Register

PS037363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel